Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only


| Attribute | ||
|---|---|---|
Research Summary | Ipamorelin is the cleanest growth hormone booster. It gently nudges your brain to release growth hormone without making you hungry or raising your stress hormones. It is perfect for steady, long-term anti-aging. | This is the perfect team for boosting growth hormone. CJC opens the door, and Ipamorelin pushes the hormone out. Together, they force the body to release a huge wave of anti-aging and fat-burning growth hormone while you sleep. |
Studied For | GH secretagogue researchAnti-aging / longevity via GH axisBody composition improvementLean muscle gainFat loss via GHSleep quality / GH rhythmRecoveryBone density via GHIGF-1 elevationPulsatile GH release simulationStacked with CJC-1295 (no DAC)GI motility researchMetabolic rate improvementCollagen synthesis via GHAthletic performanceanti-agingmuscle growthfat lossrecoverydeep sleepbone densitycellular repairGH pulse stimulation | Dual-pathway GH stimulation researchSynergistic GH releaseGHRH plus GHRP combinationMaximum GH pulse amplificationAnti-aging via GH axisBody composition improvementLean muscle gain researchFat loss via GHSleep quality and GH rhythmRecovery accelerationIGF-1 elevationBone density via dual GH stimulationAthletic performance researchGH axis optimizationLongevity via GH supportmuscle growthfat lossanti-agingdeep sleeprecoveryvitality |
Research Areas | Performance & MuscleLongevityMetabolicJoint & Bone SupportSleep & Circadian | Performance & MuscleLongevityMetabolicJoint & Bone SupportSleep & Circadian |
Best Stacked With | cjc-1295-no-dacsermorelinghrp-2bac-water | sermorelintesamorelinbac-water |
Overview | ||
Category | Muscle Growth & Performance | Peptide Stacks |
Compound Class | Selective synthetic pentapeptide GH secretagogue (GHRP); minimal cortisol/prolactin side effects | Peptide stack: GHRH analog (CJC-1295 no-DAC) + selective GHRP (Ipamorelin) |
Molecular Target | GHS-R1a (ghrelin receptor) agonist; highly selective for pituitary GH release without significant ACTH/cortisol elevation | Dual: GHRH receptor (CJC component) + ghrelin/GHS-R1a receptor (Ipamorelin component); synergistic pituitary GH release |
Aliases / AKA | NNC 26-0161NNC26-0161Ipamorelin acetateGHRP-1a analogSelective GHRPIpamorelin peptide | CJC IPA stackCJC+IpamorelinCJC Ipamorelin blendMod GRF Ipamorelin stackCJC ipamorelin comboCJC-1295 ipamorelin |
Parent Compound | Ghrelin mimetic | CJC-1295 and Ipamorelin |
Molecular Weight | 711.85 Da | combination |
Amino Acid Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | CJC-1295 no-DAC + Ipamorelin |
CAS Number | 170851-70-4 | n/a |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | No | No |
GLP-1 Class | No | No |
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | ||
PubMed Citations | 1,192,840 Extensive | Not Listed |
Clinical Trials | Not Listed | Not Listed |
Regulatory Status | Not FDA-approved; research chemical; WADA S2. | Not FDA-approved; WADA S2. |
Evidence & Regulatory | ||
Half-Life | ~2 hours | ~30 min (CJC) / ~2 hours (Ipamorelin) |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | Preclinical work established growth-hormone release with no rise in cortisol or prolactin. A human GI-motility program was run and discontinued for non-safety reasons. | The GHRH-plus-GHRP synergy is well supported by human physiology studies; controlled data for this specific research-chemical pairing are limited. |
Side Effects Noted | Best tolerated of the GHRPs; injection-site reactions, flushing, headache, mild water retention; limited human data. | Inherits both components: injection-site reactions, flushing, water retention; ipamorelin spares cortisol and prolactin. |
Warnings | Not approved; growth-hormone-axis risks apply with sustained use. WADA-prohibited. Research use only. | Both components are unapproved and WADA-prohibited. Research use only. |
Pharmacology | ||
Form | lyophilized | lyophilized |
Diluent | bacteriostatic or sterile water | bacteriostatic or sterile water |
Storage Temp | cold, dark | cold, dark |
Light Sensitive | Yes | Yes |
Freeze / Thaw | avoid | avoid |
Handling Notes | Most selective GHRP; often paired with a GHRH analog. | No-DAC chosen for pulsatile release. |
Reconstituted Shelf Life | 28 Days Refrigerated | 28 Days Refrigerated |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Two leading tissue-repair peptides with distinct healing mechanisms.
A systemic repair peptide versus a copper peptide for tissue and skin research.
A GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis.
A dual incretin agonist versus an amylin analog in metabolic research.
A triple incretin agonist versus an amylin analog in weight research.
Two metabolic research compounds targeting mitochondrial and NNMT pathways.
NAD+ metabolism versus a mitochondrial-derived peptide in longevity research.
Two copper research peptides studied for skin and hair.
A long-acting versus a short-acting GHRH analog.
A selective versus a first-generation ghrelin-receptor secretagogue.
A GLP-1 agonist versus a GLP-1/amylin combination in metabolic research.
Two peptides studied for gut and mucosal repair.
Melanocortin versus oxytocin pathways in intimacy and libido research.
Two thymic immune-modulating research peptides.
An anxiolytic nootropic versus a sleep-associated research peptide.
Direct IGF-1 signaling versus myostatin inhibition in muscle research.
A mitochondrial-targeted peptide versus NAD+ in cellular-energy research.
Single BPC-157 versus the combined BPC-157 and TB-500 blend in recovery research.
Ipamorelin alone versus the CJC-1295 and ipamorelin blend on the growth-hormone axis.
A synthetic ACTH-fragment nootropic versus a neurotrophic peptide preparation in cognitive research.
Two sleep-research compounds with distinct mechanisms.
A copper tripeptide versus an acetyl hexapeptide in cosmetic and skin research.
A senolytic peptide versus a telomerase-pathway peptide in longevity research.
Two metabolic research compounds targeting the AMPK and NNMT pathways.
A GHRH analog versus an HGH fragment in fat-metabolism research.
Two AMPK-associated mitochondrial and metabolic research compounds.
Two peptides studied for tissue protection and repair.
Two peptides studied for immune and inflammatory modulation.
Two peptide bioregulators studied in longevity and neuro research.
A glucagon/GLP-1 dual agonist versus a GIP/GLP-1 dual agonist in metabolic research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.